Jason Hsu

Co-Director of Retina Research @Wills_Eye | Retina Surgeon @MidAtl_Retina | Professor @JeffersonUniv

[Jason Hsu @JasonHsuMD]

Happy to share three on-demand short CME courses on managing patients with wet AMD sponsored by the American Academy of Ophthalmology and co-moderated by Mrinali Gupta and myself. (1) https://t.co/ReL0UqJVvK (2) https://t.co/rkYOEvbbWV (3) https://t.co/xDYIXC2GEI

[Jason Hsu @JasonHsuMD]

Excited to announce our analysis of DRCR Protocol AC (Avastin first vs. Eylea only for Diabetic Macular Edema). Eylea only subjects achieved absence of DME and very good vision ~3 months sooner, suggesting a downside to step therapy with Avastin first. https://t.co/2jj8EtUgEP

[Jason Hsu @JasonHsuMD]

In patients with high genetic risk for #AMD progression, healthy lifestyle behaviors could still lower risk of advanced AMD. 55-60% of development of advanced AMD is due to these lifestyle factors. Presented by Joanna Seddon at #RSLisbon2024 @RetinaSociety

[Jason Hsu @JasonHsuMD]

Use of levodopa was associated with 32% reduced development of new-onset geographic atrophy. It may dilate choroidal vasculature or reduce oxidative stress. However difficult to determine effect of Parkinson’s. Presented by Jeremy Lavine at #RSLisbon2024 @RetinaSociety

[Jason Hsu @JasonHsuMD]

Metformin use shown to be associated with lower risk of new #AMD and dry AMD. Presentation at #RSLisbon2024 by Dmitra Skondra shows association between metformin use and 47% reduced odds of geographic atrophy in patients without diabetes @RetinaSociety

[Jason Hsu @JasonHsuMD]

Faricimab associated with greater reductions in pigment epithelial detachment. Better early drying of fluid associated with greater likelihood of extension to 16 weeks. Over 50% could have been extended to 20 weeks. Terrific talks at #RSLisbon2023 @RetinaSociety @TheIVIpodcast

[Jason Hsu @JasonHsuMD]

Phase 2 subretinal gene therapy of ABBV-RGX-314 in previously treated wet AMD showed good tolerance with few cases of inflammation responsive to steroid drops + stable vision and edema with over 70% injection free over 6 mos. @allenho #RSLisbon2024 @RetinaSociety @Wills_Eye

[Jason Hsu @JasonHsuMD]

Study of real world use of Eylea HD by >300 retina docs showed mean extension of 14 days by the 4th EHD injection compared to interval prior to being switched. Low rates of adverse events. Presented by @NJRetinaDoc at #RSLisbon2024 @RetinaSociety @MidAtl_Retina @Wills_Eye

[Jason Hsu @JasonHsuMD]

Fascinating study on use of intravitreal methotrexate and rituximab for treatment of bilateral diffuse uveal melanocytic proliferation presented by Jasmine Francis at #RSLisbon2024, showing potential for long term vision improvement and preservation. @RetinaSociety

[Jason Hsu @JasonHsuMD]

Genome wide association study found central serous retinopathy was associated with vascular endothelial protein tyrosine phosphatase which is modulated by faricimab. @LizzyRossin presented a small case series showing fluid resolution with faricimab injections #RSLisbon2024

[Jason Hsu @JasonHsuMD]

Smaller ellipsoid zone lesion size, younger age, and lack of foveal involvement portended a greater reduction in disease progression with NT-501 (encapsulated cell technology) for macular telangiectasis type 2. Presented by Anthony Capone at #RSLisbon2024 @RetinaSociety

[Jason Hsu @JasonHsuMD]

Very interesting study by @GlennYiuMD at #RSLisbon2024 about modifying rod photoreceptors to be more cone-like in order to mitigate retinal pigment epithelial atrophy in a geographic atrophy animal model. @RetinaSociety

[Jason Hsu @JasonHsuMD]

Phase 2 trial of bel-sar for choroidal melanoma showed 80% local tumor control rate with 90% having vision preservation and a very good safety profile presented by Ivana Kim at #RSLisbon2024 @RetinaSociety

[Jason Hsu @JasonHsuMD]

Outstanding talk by @eyeamprithvi at #RSLisbon2024 on his study of using aqueous humor to determine metastatic risk potential of uveal melanoma @RetinaSociety

[Jason Hsu @JasonHsuMD]

Fantastic diabetic retinopathy session at #RSLisbon2024 with three great talks focusing on health disparities and inequities in diabetic retinopathy by @DrKNwan, Brian VanderBeek, and Anjali Shah @RetinaSociety

[Jason Hsu @JasonHsuMD]

Concept of suprachoroidal injection of viscoelastic in rhegmatgenous retina detachment to create a temporary buckle without need for gas or positioning. Terrific presentation of 6 cases by Rajeev Muni at #RSLisbon2024 @RetinaSociety

[Ophthalmology @AAOjournal]

New #OphthalmologyJournal #Podcast! @iDrFeng interviews @momenaeib & @JasonHsuMD on the incidence, timing, risk factors, and outcomes of recurrent retinal detachment after phacoemulsification
https://t.co/PS2zi2nI2q

[Jason Hsu @JasonHsuMD]

Thanks @SArepalliMD @RetinalPhys for highlighting our study which found that cumulative endophthalmitis risk seems to decrease with greater number of intravitreal injections. Check out the article for some of our hypotheses

[Retinal Physician @RetinalPhys]

Exploring Risk of #Endophthalmitis With Intravitreal Injections: A recent report assessed the cumulative risk of endophthalmitis. By Sruthi Arepalli, MD https://t.co/qSDSQ5QhY4 #uveitis #ophthalmology

[Jason Hsu @JasonHsuMD]

Enjoyed this opportunity to better understand how #MacularDegeneration impacts our patients and how what we do as retina specialists can help improve quality of life

[Med Learning Group @MLG_CME]

Experience a unique CME Activity w/ @JasonHsuMD that takes you on a patient journey with nAMD.

Gain insights into various therapies and discover the latest technological updates.

👉https://t.co/lOsrPbLVRN

#CME #MedEd #Ophthalmology #MacularDegeneration #optometry

[Jason Hsu @JasonHsuMD]

The risk of post-injection endophthalmitis doesn’t increase linearly as patients receive more injections but is higher early on and lower later in the course of treatment. Check out our theories: https://t.co/o4pf9iNUKG @RIsrailevichMD @HanaMansourMD @YoshiYonekawaMD @Wills_Eye